Drug intelligence / Profile preview

HLX43 + HLX10 + HLX07

Development stage: Unknown
Lead developer: Henlius
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

HLX43 + HLX10 + HLX07 is a combination therapy developed by Shanghai Henlius Biotech for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The regimen consists of HLX43, a potential best-in-class antibody-drug conjugate (ADC) targeting PD-L1; HLX10 (serplulimab), a humanized monoclonal antibody targeting the PD-1 immune checkpoint; and HLX07, a recombinant humanized monoclonal antibody targeting the epidermal growth factor receptor (EGFR). HLX43 utilizes MediLink Therapeutics' TMALIN® technology to conjugate a topoisomerase I inhibitor payload to an anti-PD-L1 antibody with a drug-antibody ratio (DAR) of 8. This triple combination aims to leverage the synergistic effects of immune checkpoint blockade (PD-1/PD-L1) and EGFR inhibition alongside payload-mediated cytotoxicity to overcome resistance and improve outcomes in HNSCC.

Other names: HLX43 + serplulimab + HLX07

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on HLX43 + HLX10 + HLX07.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HLX43 + HLX10 + HLX07.

Explore the full profile